Skip to content
Research Article Open access CC BY 3.0

Role of Magnesium Supplement on Hyperlipidemia and L-CAT Level in Patient on Atorvastatin Therapy

Sahar M. El-Haggar, Tarek M. Mostafa

Journal of Pharmaceutical Research International · pp. 1521–1534 · Published 18 Jun 2014

10.9734/BJPR/2014/11145

Abstract

Aim: This study aimed to evaluate the effect of magnesium supplement to atorvastatin on hyperlipidemic patients and to elucidate the possible ability of oral magnesium supplement to counteract or delay statins induced myalgia. Study Design: Forty hyperlipidemic male and female patients were randomly divided into two groups: group one consisted of twenty patients, who received atorvastatin 10 mg once daily for 6 weeks then 20 mg once daily for another 6 weeks; group two consisted of twenty patients, who received the same dose of atorvastatin plus once daily oral low dose magnesium sulfate trihydrate 419.5 mg equivalent to 50 mg of magnesium. Place and Duration of Study: The Laboratory of Pharmaceutical Research Center of Faculty of Pharmacy, Tanta University, Egypt, between July to December 2013. Methodology: Two samples of venous blood (2 ml + 8 ml =10 ml total), were collected from all individuals, and were drawn from the antecubital vein before, 1.5 and 3 months after treatment. Sera and plasma were separated immediately for biochemical analyses of lecithin cholesterol acyltransferase (L-CAT) (ELISA), creatine kinase (CK), serum Ca+, Mg++, Na+, K+, lipid profile and aspartate transaminase (AST) (colorimetrically), and serum creatinine (S.Cr) spectrophotometrically. Results: The statistical analysis revealed that, 3 months after treatment, both groups showed significant amelioration in lipid profiles and significant elevation in L-CAT level regarding to baseline data obtained before initiation of treatment. In addition, the patients received atorvastatin plus magnesium supplement showed significantly higher levels of serum magnesium, plasma L-CAT and HDL-cholesterol concentrations and significantly lower total cholesterol, LDL-cholesterol and triglycerides concentrations with non significant lower CK level as compared to the patients group received atorvastatin solely. Conclusion: Mg++ supplement to atorvastatin improve all lipid profile and provide better control on dyslipidemia than atorvastatin alone. However, Mg++ supplement to atorvastatin doesn’t prevent elevation in CK; it may delay and provide some protection against statin induced myopathy that in turn may increase patient compliance.

Hyperlipidemia atorvastatin magnesium lipid profiles L-CAT.

References (47)

  1. 1 Tietz Textbook of Clinical Chemistry [DOI]
  2. 2 The plasma lecithin:cholesterol acyltransferase reaction [DOI]
  3. 3 Statin-Associated Myopathy [DOI]
  4. 4 Statin-induced inhibition of the Rho-signaling pathway activates PPARα and induces HDL apoA-I [DOI]
  5. 5 Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL [DOI]
  6. 6 Comparison of Statins in Hypertriglyceridemia [DOI]
  7. 7 Magnesium Intake, C-Reactive Protein, and the Prevalence of Metabolic Syndrome in Middle-Aged and Older U.S. Women [DOI]
  8. 8 Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo [DOI]
  9. 9 Effects of Statins on 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition Beyond Low-Density Lipoprotein Cholesterol [DOI]
  10. 10 Low serum magnesium levels and metabolic syndrome [DOI]
  11. 11 Effects of Intensive Versus Moderate Lipid-Lowering Therapy on Myocardial Ischemia in Older Patients With Coronary Heart Disease [DOI]
  12. 12 Magnesium intake and plasma concentrations of markers of systemic inflammation and endothelial dysfunction in women [DOI]
  13. 13 Lipid-Lowering Agents That Cause Drug-Induced Hepatotoxicity [DOI]
  14. 14 Effect of Statins on Cholesterol Crystallization and Atherosclerotic Plaque Stabilization [DOI]
  15. 15 Serum Ionized Magnesium Levels in Relation to Metabolic Syndrome in Type 2 Diabetic Patients [DOI]
  16. 16 Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. [DOI]
  17. 17 The mechanism of the plasma cholesterol esterification reaction: Plasma fatty acid transferase [DOI]
  18. 18 Role of plasma lecithin:cholesterol acyltransferase in the metabolism of high density lipoproteins [DOI]
  19. 19 Action of Atorvastatin in Combined Hyperlipidemia [DOI]
  20. 20 Improved Insulin Response and Action by Chronic Magnesium Administration in Aged NIDDM Subjects [DOI]
  21. 21 The effects of high oral magnesium supplementation on blood pressure, serum lipids and related variables in apparently healthy Japanese subjects [DOI]
  22. 22 Myotoxicity associated with lipid-lowering drugs [DOI]
  23. 23 The influence of calcium and magnesium in drinking water and diet on cardiovascular risk factors in individuals living in hard and soft water areas with differences in cardiovascular mortality [DOI]
  24. 24 Comparison of Mechanism and Functional Effects of Magnesium and Statin Pharmaceuticals [DOI]
  25. 25 Hypomagnesemia is linked to low serum HDL-cholesterol irrespective of serum glucose values [DOI]
  26. 26 Dose-comparative effects of different statins on serum lipid levels: a network meta-analysis of 256,827 individuals in 181 randomized controlled trials [DOI]
  27. 27 Effect of magnesium deficiency on Δ6 desaturase activity and fatty acid composition of rat liver microsomes [DOI]
  28. 28 The effect of atorvastatin therapy on lecithin:cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase [DOI]
  29. 29 Effect of Magnesium Deficiency on Lipid Metabolism in Rats Fed a High Carbohydrate Diet [DOI]
  30. 30 Effect of Statins on Metabolism of Apo-B–Containing Lipoproteins in Hypertriglyceridemic Men [DOI]
  31. 31 Effect of moderate magnesium deficiency on serum lipids, blood pressure and cardiovascular reactivity in normotensive rats [DOI]
  32. 32 Changes of linoleic acid metabolism and cellular phospholipid fatty acid composition in LLC-PK cells cultured at low magnesium concentrations [DOI]
  33. 33 Correlation of Serum Magnesium and Serum Lipid Levels in Hemodialysis Patients [DOI]
  34. 34 Cholesterol esterification by lecithin-cholesterol acyltransferase in A-I-free plasma [DOI]
  35. 35 Role of magnesium and potassium in the pathogenesis of arteriosclerosis.
  36. 36 Effect of magnesium deficiency on post‐heparin lipase activity and tissue lipoprotein lipase in the rat [DOI]
  37. 37 Interrelationships of magnesium and potassium homeostasis.
  38. 38 Lecithin:cholesterol acyltransferase activity in patients with acute myocardial infarction and coronary heart disease.
  39. 39 Effects of atorvastatin on high‐density lipoprotein apolipoprotein A‐I metabolism in dogs [DOI]
  40. 40 Evolving concepts in epithelial magnesium transport [DOI]
  41. 41 Benefit and tolerability of the coadministration of ezetimibe and atorvastatin in acute coronary syndrome patients.
  42. 42 Magnesium, lipids and vascular diseases. Experimental evidence in animal models.
  43. 43 Reduction of Plasma Lecithin—Cholesterol Acyltransferase Activity by Acute Magnesium Deficiency in the Rat [DOI]
  44. 44 Atorvastatin and the plasma activities of lipoprotein lipase, hepatic lipase and lecithin:cholesterol acyltransferase in patients with mixed hyperlipidemia [DOI]
  45. 45 Correlation of serum HDL-cholesterol and LCAT levels with the fraction of ionized magnesium in children.
  46. 46 Statin Trials and Goals of Cholesterol-Lowering Therapy [DOI]
  47. 47 PO23-762 THE EFFECT OF ATORVASTATIN THERAPY ON HDL SUBFRACTIONS, LECITHIN:CHOLESTEROL ACYLTRANSFERASE, CHOLESTERYL ESTER TRANSFER PROTEIN AND HUMAN PARAOXONASE-1 [DOI]

Cited by 2

The Link between Magnesium Supplements and Statin Medication in Dyslipidemic Patients

Roxana Nartea, Brindusa Ilinca Mitoiu, Ioana Ghiorghiu · Current Issues in Molecular Biology · 2023

Showing 1 of 2 known citations — external sources report more than can currently be individually listed.

Related research

Article metrics

Real usage data collected on this platform.

12

Page views

0

PDF downloads

10

Outbound clicks

2

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.